CAJ | 학술논문

目的：探讨不同年龄的下肢深静脉血栓（ deep venous thrombosis ，DVT）患者口服华法林的最佳初始剂量。方法我科2012年1月至2013年10月收治112例急性下肢深静脉血栓患者，根据患者年龄分为甲、乙、丙三组，并给予不同的初始剂量，甲组27例（＜51岁，初始剂量3.75 mg），乙组52例（51～70岁，初始剂量2.5 mg），丙组33例（＞70岁，初始剂量1.25 mg）。通过监测国际化标准比值（ INR）调整华法林用量，监测三组患者INR达到2.0～3.0时的时间及华法林维持剂量。结果 INR达到2.0～3.0时，甲组用时（7.2±1.2）d，华法林剂量为（4.23±0.82）mg；乙组用时（9.3±1.5）d，华法林剂量为（4.05±0.64）mg；丙组用时（9.7±0.7）d，华法林剂量为（3.32±0.45）mg。结论对于不同年龄的急性DVT患者，可选择不同的华法林初始剂量，使患者更快、更安全的达到维持剂量。
목적：탐토불동년령적하지심정맥혈전（ deep venous thrombosis ，DVT）환자구복화법림적최가초시제량。방법아과2012년1월지2013년10월수치112례급성하지심정맥혈전환자，근거환자년령분위갑、을、병삼조，병급여불동적초시제량，갑조27례（＜51세，초시제량3.75 mg），을조52례（51～70세，초시제량2.5 mg），병조33례（＞70세，초시제량1.25 mg）。통과감측국제화표준비치（ INR）조정화법림용량，감측삼조환자INR체도2.0～3.0시적시간급화법림유지제량。결과 INR체도2.0～3.0시，갑조용시（7.2±1.2）d，화법림제량위（4.23±0.82）mg；을조용시（9.3±1.5）d，화법림제량위（4.05±0.64）mg；병조용시（9.7±0.7）d，화법림제량위（3.32±0.45）mg。결론대우불동년령적급성DVT환자，가선택불동적화법림초시제량，사환자경쾌、경안전적체도유지제량。
Objective To explore the optimal initial doses of oral warfarin in treatment of patients with deep venous thrombosis ( DVT) in different ages .Methods One hundred and twelve patients with acute DVT were received and cured in our department from January 2012 to October 2013.The patients were divided into A ,B and C groups according to the patient's age.The three groups were given different initial dose.The group A (n =27 with age <51 years old) was give an initial dose of 3.75 mg.The group B (n =52 with age 51-70 years old) was given an initial dose of 2.5 mg.The group C (n =33 with age>70 years old) was given an initial dose of 1.25 mg.The warfarin doses were adjusted through monitoring INR .The time of reaching INR 2.0-3.0 and warfarin maintenance do-ses were monitored.Results The time of reaching INR 2.0-3.0 was(7.2 ±1.2)d in the group A,(9.3 ±1.5)d in the group B and (9.7 ±0.7)d in the group C,respectively.The maintenance warfarin doses were (4.23 ±0.82)mg in the group A,(4.05 ±0.64)mg in the group B and (3.32 ±0.45)mg in the group C,respectively.Conclusion For acute DVT patients,an initial dose of warfarin should be selected according to ages of patients so that patients could reach the maintenance doses faster and safer .